BioSpace2 天
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...
Fierce Pharma3 天
Merck's Winrevair slashes mortality-morbidity risk by 76%
The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
2 Minute Medicine9 天
Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule
Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...
MPR3 天
Sotatercept Reduces Major Events in High-Risk PAH Patients
Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...
The Scientist1 年
Introducing GMP-Grade Recombinant Cytokines for Stem Cell Research
Stem cells are particularly useful models for discovering and validating novel pharmacological targets, particularly for precision medicine applications for which a patient’s own ... Other cytokines, ...